Literature DB >> 21454581

Crystal structure of leukocyte Ig-like receptor LILRB4 (ILT3/LIR-5/CD85k): a myeloid inhibitory receptor involved in immune tolerance.

Hao Cheng1, Fiyaz Mohammed, Gol Nam, Yong Chen, Jianxun Qi, Lee I Garner, Rachel L Allen, Jinghua Yan, Benjamin E Willcox, George F Gao.   

Abstract

The myeloid inhibitory receptor LILRB4 (also called ILT3, LIR-5, CD85k), a member of the leukocyte immunoglobulin-like receptors (LILRs/LIRs), is an important mediator of immune tolerance. Up-regulated on tolerogenic dendritic cells, it has been shown to modulate immune responses via induction of T cell anergy and differentiation of CD8(+) T suppressor cells and may play a role in establishing immune tolerance in cancer. Consequently, characterizing the molecular mechanisms involved in LILRB4 function and in particular its structure and ligands is a key aim but has remained elusive to date. Here we describe the production, crystallization, and structure of the LILRB4 ectodomain to 1.7 Å using an expression strategy involving engineering of an additional disulfide bond in the D2 domain to enhance protein stability. LILRB4 comprises two immunoglobulin domains similar in structure to other LILRs; however, the D2 domain, which is most closely related to the D4 domains of other family members, contains 3(10) helices not previously observed. At the D1-D2 interface, reduced interdomain contacts resulted in an obtuse interdomain angle of ∼107°. Comparison with MHC class I binding Group 1 LILRs suggests LILRB4 is both conformationally and electrostatically unsuited to MHC ligation, consistent with LILRB4 status as a Group 2 LILR likely to bind novel non-MHC class I ligands. Finally, examination of the LILRB4 surface highlighted distinctive surface patches on the D1 domain and D1D2 hinge region, which may be involved in ligand binding. These findings will facilitate our attempts to precisely define the role of LILRB4 in the regulation of immune tolerance.
© 2011 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21454581      PMCID: PMC3093875          DOI: 10.1074/jbc.M111.221028

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  64 in total

1.  Production of soluble alphabeta T-cell receptor heterodimers suitable for biophysical analysis of ligand binding.

Authors:  B E Willcox; G F Gao; J R Wyer; C A O'Callaghan; J M Boulter; E Y Jones; P A van der Merwe; J I Bell; B K Jakobsen
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

2.  The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18.

Authors:  T L Chapman; A P Heikeman; P J Bjorkman
Journal:  Immunity       Date:  1999-11       Impact factor: 31.745

Review 3.  A family of inhibitory and activating Ig-like receptors that modulate function of lymphoid and myeloid cells.

Authors:  M Colonna; H Nakajima; M Cella
Journal:  Semin Immunol       Date:  2000-04       Impact factor: 11.130

4.  SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model.

Authors:  A A Vaguine; J Richelle; S J Wodak
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1999-01-01

5.  Crystal structure of the HLA-Cw3 allotype-specific killer cell inhibitory receptor KIR2DL2.

Authors:  G A Snyder; A G Brooks; P D Sun
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

6.  Crystal structure and ligand binding properties of the D1D2 region of the inhibitory receptor LIR-1 (ILT2).

Authors:  T L Chapman; A P Heikema; A P West; P J Bjorkman
Journal:  Immunity       Date:  2000-11       Impact factor: 31.745

Review 7.  Human inhibitory and activating Ig-like receptors which modulate the function of myeloid cells.

Authors:  J Dietrich; H Nakajima; M Colonna
Journal:  Microbes Infect       Date:  2000-03       Impact factor: 2.700

8.  Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling.

Authors:  P Schuck
Journal:  Biophys J       Date:  2000-03       Impact factor: 4.033

9.  The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions.

Authors:  D Saverino; M Fabbi; F Ghiotto; A Merlo; S Bruno; D Zarcone; C Tenca; M Tiso; G Santoro; G Anastasi; D Cosman; C E Grossi; E Ciccone
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

10.  Genomic organization of the human leukocyte immunoglobulin-like receptors within the leukocyte receptor complex on chromosome 19q13.4.

Authors:  W R Liu; J Kim; C Nwankwo; L K Ashworth; J P Arm
Journal:  Immunogenetics       Date:  2000-07       Impact factor: 2.846

View more
  22 in total

Review 1.  Natural killer cells and their receptors in multiple sclerosis.

Authors:  Gurman Kaur; John Trowsdale; Lars Fugger
Journal:  Brain       Date:  2012-06-25       Impact factor: 13.501

2.  Crystal structures of the two membrane-proximal Ig-like domains (D3D4) of LILRB1/B2: alternative models for their involvement in peptide-HLA binding.

Authors:  Gol Nam; Yi Shi; Myongchol Ryu; Qihui Wang; Hao Song; Jun Liu; Jinghua Yan; Jianxun Qi; George F Gao
Journal:  Protein Cell       Date:  2013-08-17       Impact factor: 14.870

3.  Structure and flexibility of the extracellular region of the PirB receptor.

Authors:  Hedwich C Vlieg; Eric G Huizinga; Bert J C Janssen
Journal:  J Biol Chem       Date:  2019-01-23       Impact factor: 5.157

4.  Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy.

Authors:  Amira A Barkal; Kipp Weiskopf; Kevin S Kao; Sydney R Gordon; Benyamin Rosental; Ying Y Yiu; Benson M George; Maxim Markovic; Nan G Ring; Jonathan M Tsai; Kelly M McKenna; Po Yi Ho; Robin Z Cheng; James Y Chen; Layla J Barkal; Aaron M Ring; Irving L Weissman; Roy L Maute
Journal:  Nat Immunol       Date:  2017-11-27       Impact factor: 25.606

5.  Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer.

Authors:  Pauline L de Goeje; Koen Bezemer; Marlies E Heuvers; Anne-Marie C Dingemans; Harry Jm Groen; Egbert F Smit; Henk C Hoogsteden; Rudi W Hendriks; Joachim Gjv Aerts; Joost Pjj Hegmans
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

6.  Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development.

Authors:  Xun Gui; Mi Deng; Hao Song; Yuanzhi Chen; Jingjing Xie; Zunling Li; Licai He; Fangfang Huang; Yixiang Xu; Yasuaki Anami; Hai Yu; Chenyi Yu; Leike Li; Zihao Yuan; Xiaoying Xu; Qihui Wang; Yan Chai; Tao Huang; Yi Shi; Kyoji Tsuchikama; X Charlene Liao; Ningshao Xia; George F Gao; Ningyan Zhang; Cheng Cheng Zhang; Zhiqiang An
Journal:  Cancer Immunol Res       Date:  2019-06-18       Impact factor: 11.151

7.  Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity.

Authors:  Hui-Ming Chen; William van der Touw; Yuan Shuo Wang; Kyeongah Kang; Sunny Mai; Jilu Zhang; Dayanira Alsina-Beauchamp; James A Duty; Sathish Kumar Mungamuri; Bin Zhang; Thomas Moran; Richard Flavell; Stuart Aaronson; Hong-Ming Hu; Hisashi Arase; Suresh Ramanathan; Raja Flores; Ping-Ying Pan; Shu-Hsia Chen
Journal:  J Clin Invest       Date:  2018-10-22       Impact factor: 14.808

8.  Structural basis of collagen recognition by human osteoclast-associated receptor and design of osteoclastogenesis inhibitors.

Authors:  Joel Haywood; Jianxun Qi; Chun-Chi Chen; Guangwen Lu; Yingxia Liu; Jinghua Yan; Yi Shi; George F Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-07       Impact factor: 11.205

9.  Binding mode of the side-by-side two-IgV molecule CD226/DNAM-1 to its ligand CD155/Necl-5.

Authors:  Han Wang; Jianxun Qi; Shuijun Zhang; Yan Li; Shuguang Tan; George F Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-27       Impact factor: 11.205

Review 10.  Camouflage strategies for therapeutic exosomes evasion from phagocytosis.

Authors:  Nicol Parada; Alfonso Romero-Trujillo; Nicolás Georges; Francisca Alcayaga-Miranda
Journal:  J Adv Res       Date:  2021-01-08       Impact factor: 10.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.